Izvorni znanstveni članak
Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
Sabine Vogler
; Health Economics Department WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Gesundheit Österreich GmbH /Geschäftsbereich ÖBIG – Austrian Health Institute, Vienna, Austria
Claudia Habl
; Health Economics Department WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Gesundheit Österreich GmbH /Geschäftsbereich ÖBIG – Austrian Health Institute, Vienna, Austria
Martina Bogut
; Department for Drugs and Medical Products, Croatian Institute for Health Insurance, Zagreb, Croatia
Luka Vončina
; Department for Drugs and Medical Products, Croatian Institute for Health Insurance, Zagreb, Croatia
Sažetak
Aim To perform a comparative analysis of the pharmaceutical pricing and reimbursement systems in Croatia and the
27 European Union (EU) Member States.
Methods Knowledge about the pharmaceutical systems
in Croatia and the 27 EU Member States was acquired by
literature review and primary research with stakeholders.
Results Pharmaceutical prices are controlled at all levels in
Croatia, which is also the case in 21 EU Member States. Like
many EU countries, Croatia also applies external price referencing, ie, compares prices with other countries. While the
wholesale remuneration by a statutorily regulated linear
mark-up is applied in Croatia and in several EU countries,
the pharmacy compensation for dispensing reimbursable
medicines in the form of a flat rate service fee in Croatia
is rare among EU countries, which usually apply a linear
or regressive pharmacy mark-up scheme. Like in most EU
countries, the Croatian Social Insurance reimburses specific medicines at 100%, whereas patients are charged copayments for other reimbursable medicines. Criteria for reimbursement include the medicine’s importance from the
public health perspective, its therapeutic value, and relative
effectiveness. In Croatia and in many EU Member States, reimbursement is based on a reference price system.
Conclusion The Croatian pharmaceutical system is similar
to those in the EU Member States. Key policies, like external price referencing and reference price systems, which
have increasingly been introduced in EU countries are also
applied in Croatia and serve the same purpose: to ensure
access to medicines while containing public pharmaceutical expenditure
Ključne riječi
Hrčak ID:
71431
URI
Datum izdavanja:
15.4.2011.
Posjeta: 2.908 *